Ulvac (6728) · InitiativeReframed
Approximately ¥50 billion in R&D investment over 3 years
First written in FY2017. 1 of 4 entries say "Restated". Latest entry: FY2020.
4entries
4years
0from disclosures
How it moved
Same theme, other companies
Capital Expenditure and Research and Development Investment Allocation in the Medium-Term PlanA theme 7 companies write about · 0 as a headwind · 7 as a tailwind
Ulvac moved to the "Worse" side of this theme in 2020.
0 other companies' latest entry also says "Reframed".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020ReframedAnnual report
「① Basic policies ・Development investment for growth (selectivity and concentration) ・Profit-focused management through a transformation of the Company's business structure」
The former specific target of approximately ¥50 billion in R&D investment over 3 years was reformulated as a policy of selectively concentrating development investment in growth areas. - FY2019DroppedAnnual reportThe current year's priorities do not specify the individual numerical target of approximately ¥50 billion in R&D investment over 3 years. R&D investment itself is continuing.
- FY2018RestatedAnnual report
「Increase R&D investment (*) to approximately ¥50 billion over 3 years」
The measure to increase R&D investment to approximately ¥50 billion over 3 years remained a core element of the plan. R&D expenses for the current fiscal year were stated as ¥8.293 billion. - FY2017First statedAnnual report
「Increase R&D investment (*) to approximately ¥50 billion over 3 years」
A measure to increase combined capital investment in R&D facilities and R&D expenses to approximately ¥50 billion over 3 years.